| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $142.7M | +46.8% |
| SG&A Expense | $29.6M | +5.8% |
| Operating Income | -$172.2M | -37.6% |
| Interest Expense | $2.0M | +167.9% |
| Income Tax | $0 | — |
| Net Income | -$167.9M | -44.9% |
| EPS (Basic) | -$2.10 | +10.3% |
| EPS (Diluted) | -$2.10 | +10.3% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $83.0M | -49.4% |
| Short-term Investments | $50.6M | — |
| Current Assets | $138.9M | -16.7% |
| Total Assets | $165.1M | -10.8% |
| Current Liabilities | $50.2M | +85.2% |
| Total Liabilities | $53.0M | +62.1% |
| Stockholders' Equity | $112.1M | -26.4% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$131.1M | -48.6% |
| Capital Expenditures | $1.2M | -44.4% |
| Investing Cash Flow | -$50.3M | -206.3% |
| Financing Cash Flow | $100.3M | +759.4% |
| Free Cash Flow | -$132.3M | -46.3% |